Abstract
| Language | English |
|---|---|
| Pages | 1589-1593 |
| Journal | BRITISH JOURNAL OF CANCER |
| Volume | 83 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2000 |
Fingerprint
Cite this
}
AQ4N: a new approach to hypoxia-activated cancer chemotherapy. / Patterson, LH; McKeown, Stephanie.
In: BRITISH JOURNAL OF CANCER, Vol. 83, No. 12, 12.2000, p. 1589-1593.Research output: Contribution to journal › Article
TY - JOUR
T1 - AQ4N: a new approach to hypoxia-activated cancer chemotherapy
AU - Patterson, LH
AU - McKeown, Stephanie
PY - 2000/12
Y1 - 2000/12
N2 - Preclinical studies demonstrate that in vivo AQ4N enhances the anti-tumour effects of radiation and chemotherapeutic agents with a dose-modifying factor of approximately 2.0. With careful scheduling no, or very little, additional normal tissue toxicity should be observed. AQ4N is a bioreductive prodrug of a potent, stable, reduction product which binds non-covalently to DNA, facilitating antitumour activity in both hypoxic and proximate oxic tumour cells. AQ4N is clearly different in both its mechanism of action and potential bystander effect compared to previously identified bioreductive drugs. In particular AQ4N is the only bioreductive prodrug topoisomerase II inhibitor to enter clinical trials. Targeting this enzyme, which is crucial to cell division, may help sensitize tumours to repeated (fractionated) courses of radiotherapy. This is because in principle, the bioreduction product of AQ4N can inhibit the topoisomerase activity of hypoxic cells as they attempt to re-enter the cell cycle. (C) 2000 Cancer Research Campaign.
AB - Preclinical studies demonstrate that in vivo AQ4N enhances the anti-tumour effects of radiation and chemotherapeutic agents with a dose-modifying factor of approximately 2.0. With careful scheduling no, or very little, additional normal tissue toxicity should be observed. AQ4N is a bioreductive prodrug of a potent, stable, reduction product which binds non-covalently to DNA, facilitating antitumour activity in both hypoxic and proximate oxic tumour cells. AQ4N is clearly different in both its mechanism of action and potential bystander effect compared to previously identified bioreductive drugs. In particular AQ4N is the only bioreductive prodrug topoisomerase II inhibitor to enter clinical trials. Targeting this enzyme, which is crucial to cell division, may help sensitize tumours to repeated (fractionated) courses of radiotherapy. This is because in principle, the bioreduction product of AQ4N can inhibit the topoisomerase activity of hypoxic cells as they attempt to re-enter the cell cycle. (C) 2000 Cancer Research Campaign.
U2 - 10.1054/bjoc.2000.1564
DO - 10.1054/bjoc.2000.1564
M3 - Article
VL - 83
SP - 1589
EP - 1593
JO - BRITISH JOURNAL OF CANCER
T2 - BRITISH JOURNAL OF CANCER
JF - BRITISH JOURNAL OF CANCER
SN - 0007-0920
IS - 12
ER -